Largely on the strength of its HIV franchise, Gilead Sciences Inc. reported a 55 percent income hike for the third quarter, but the company said beginning work on two more potential drugs for the virus will be stopped because of experimental results that have been less than encouraging. (BioWorld Today)

Chiron Corp. released its third-quarter earnings Wednesday, and while those figures were better than expected, the Fluvirin disaster has faded their importance. (BioWorld Today)

Genzyme Corp. reported third-quarter numbers that beat consensus estimates, and the diversification plans the company put in place over the past year are taking hold, it said. (BioWorld Today)